US equities
|
NVDA
$150.96
▼-2.89%
MU
$705.27
▼-1.00%
AMD
$530.14
▲+5.31%
SPCX
$143.50
▲+1.27%
AAPL
$352.45
▲+0.15%
MSFT
$508.29
▲+0.40%
AMZN
$267.74
▲+3.82%
TSLA
$383.72
▲+0.95%
NVDA
$150.96
▼-2.89%
MU
$705.27
▼-1.00%
AMD
$530.14
▲+5.31%
SPCX
$143.50
▲+1.27%
AAPL
$352.45
▲+0.15%
MSFT
$508.29
▲+0.40%
AMZN
$267.74
▲+3.82%
TSLA
$383.72
▲+0.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Latest News about Ami Fadia
Recent news which mentions Ami Fadia
Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish
April 15, 2025
Tickers
NBIX
Tags
Health Care
Stories That Matter
Analyst Ratings
From
Benzinga
7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%
September 28, 2022
Tickers
BIIB
Tags
BofA Securities
Danielle Brill
RBC Capital Markets
From
Benzinga
Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst
September 23, 2021
Tickers
BIIB
Tags
Initiation
Price Target
Alzheimer's disease
From
Benzinga